Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation
Authors:
- Darren M. BrennerDBDarren M. Brenner
- Gregory S. SayukGSGregory S. Sayuk
- Brooks D. CashBCBrooks D. Cash
- Lucinda A. HarrisLHLucinda A. Harris
- Nitin K. AhujaNANitin K. Ahuja
- Jill K. DeutschJDJill K. Deutsch
- Yang YangYYYang Yang
- Suling ZhaoSZSuling Zhao
- David P. RosenbaumDRDavid P. Rosenbaum
- Anthony J. LemboALAnthony J. Lembo
Open Access
- 19 December 2024
- journal article
- Published by S. Karger AG in Digestive Diseases
- Vol. 43 (2) , 146-157
Abstract
Introduction: Tenapanor is a first-in-class, minimally absorbed intestinal sodium/hydrogen exchanger isoform 3 inhibitor approved by the US Food and Drug Administration for adults with irritable bowel syndrome with constipation (IBS-C). Pooled data from the phase 2b (NCT01923428) and phase 3 T3MPO-1 (NCT02621892) and T3MPO-2 (NCT02686138) studies examined the effects of tenapanor on abdominal symptoms independent of tenapanor’s effect on complete spontaneous bowel movement (CSBM) frequency in adults with IBS-C. Methods: This post hoc analysis was performed for patients with no CSBMs in ≥6 of the first 12 weeks of treatment (no-CSBM subgroup). The three-item abdominal score (AS3; the average of weekly abdominal pain, bloating, and discomfort scores) measured abdominal symptom response in tenapanor versus placebo. The overall change from baseline and response rate (improvement of ≥2 points or a reduction of ≥30%) in AS3 and individual abdominal scores during the 12 weeks were assessed. Results: In the pooled safety analysis set (N = 1,382), 641 patients were classified as no-CSBM patients and 640 were included in the efficacy analysis. Among the no-CSBM subgroup, tenapanor-treated patients experienced a greater improvement in AS3 in week 12 versus placebo-treated patients (least squares mean change, −1.74 vs. −1.29; p = 0.007), and the AS3 responder rate was higher for tenapanor (40.2% vs. 29.6%; p = 0.008). Similar improvements were displayed across individual abdominal symptom scores. Diarrhea was the most common adverse event in tenapanor-treated patients. Conclusion: Tenapanor was observed to improve abdominal symptoms independent of its effect on bowel symptoms in adults with IBS-C.Keywords
This publication has 36 references indexed in Scilit:
- Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety TrialAmerican Journal of Gastroenterology, 2017
- What Is New in Rome IVJournal of Neurogastroenterology and Motility, 2017
- The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel TreatmentsJournal of Neurogastroenterology and Motility, 2016
- A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteersClinical and Experimental Nephrology, 2016
- Irritable bowel syndromeNature Reviews Disease Primers, 2016
- The role of mast cells in functional GI disordersGut, 2015
- The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease BurdenAmerican Journal of Gastroenterology, 2015
- Over-expression of COX-2 mRNA in colorectal cancerBMC Gastroenterology, 2014
- Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and SafetyAmerican Journal of Gastroenterology, 2012
- Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome – results of two randomized, placebo‐controlled studiesAlimentary Pharmacology & Therapeutics, 2008